Novartis AG
ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF
Last updated:
Abstract:
This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
Status:
Application
Type:
Utility
Filling date:
18 Dec 2019
Issue date:
25 Jun 2020